Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity |
| |
| Authors: | l.,bueno ,f.,de ponti &dagger ,m.,fried &Dagger ,g. a.,kullak-ublick § ,m. a.,kwiatek &Dagger ,d.,pohl &Dagger ,e. m. m.,quigley ¶ ,j.,tack ,n. j.,talley &dagger &dagger |
| |
| Affiliation: | Neurogastroenterology Unit INRA, Toulouse, France; Department of Pharmacology, University of Bologna, Bologna, Italy; Division of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland; Division of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland; Alimentary Pharmabiotic Centre, University College, Cork, Ireland; Department of Gastroenterology, University of Leuven, Leuven, Belgium; Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Dyspepsia Center, Mayo Clinic College of Medicine, Rochester, MN, USA |
| |
| Abstract: | Abstract Visceral hypersensitivity is considered a key mechanism in the pathogenesis of functional gastrointestinal (GI) disorders. Targeting visceral hypersensitivity seems an attractive approach to the development of drugs for functional GI disorders. This review summarizes current knowledge on targets for the treatment of visceral hypersensitivity, and the status of current and future drug and probiotic treatment development, and the role of pharmacogenomic factors. |
| |
| Keywords: | abdominal pain drugs enteric flora GI disorders gut sensitivity serotonin |
|
|
